Tag: merger
-
Heart Disease Biotech Acquired in $13.1B Deal
A company developing precision medicine drugs to treat inherited heart disorders was acquired by drug maker Bristol Myers Squibb, or BMS, for $13.1 billion.
-
Cancer Screening Analytics Company Acquired in $8B Deal
A company creating a blood test to screen for multiple types of cancer is being acquired by genomics analytics company Illumina for $8 billion in cash and stock.
-
Gilead Acquires Cancer Therapy Biotech for $21B
Gilead Sciences is acquiring biotechnology company Immunomedics, specializing in immunotherapies for cancer and other diseases, in a deal valued at $21 billion.
-
Food Allergy Biotech Acquired for $2.6B
Aimmune Therapeutics Inc., a developer of food allergy drugs, was acquired today by global consumer products company Nestlé for $2.6 billion.
-
Sanofi Acquires Immune Disease Biotech in $3.7B Deal
A developer of small-molecule therapies for autoimmune diseases, including multiple sclerosis, and other immune disorders is being acquired by Sanofi.
-
Infographic – Apple Leads in A.I. Acquistions
Among the tech giants, Apple is the most aggressive in acquiring start-ups developing A.I. applications over the past 10 years.
-
Merck Inks Three Covid-19 Vaccine, Therapy Deals
Drug maker Merck today gained a new acquisition, along with collaboration and licensing deals, for vaccines and a therapy for Covid-19 infections.
-
Synthetic Bio Cancer Immunotherapy Company Acquired
A biotechnology company creating synthetic proteins that invoke the immune system to fight cancer is being acquired by drug maker Astellas Pharma.
-
Synthetic Bio Company Acquired in $2.35B Deal
A company developing protein-like therapies for cancer from synthetic bacteria is being acquired by drug maker Sanofi in a deal valued at $2.35 billion.
-
Sumitomo Dainippon, Biotechs in $3B Acquisition Deal
Japanese pharmaceutical company Sumitomo Dainippon agreed to acquire five biotechnology companies and gain an equity stake in the Roivant Sciences group.